{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:19:52Z","timestamp":1783664392434,"version":"3.55.0"},"reference-count":102,"publisher":"Bioscientifica","issue":"1_Suppl","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":2017,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Both Graves\u2019 hyperthyroidism (GH) and Graves\u2019 orbitopathy (GO) are associated with significant adverse health consequences. All conventional treatment options have limitations regarding efficacy and safety. Most importantly, they do not specifically address the underlying immunological mechanisms. We aim to review the latest development of treatment approaches in these two closely related disorders. Summary: Immunotherapies of GH have recently demonstrated clinical efficacy in preliminary studies. They include ATX-GD-59, an antigen-specific immunotherapy which restores immune tolerance to the thyrotropin receptor; iscalimab, an anti-CD40 monoclonal antibody which blocks the CD40-CD154 costimulatory pathway in B-T cell interaction; and K1-70, a thyrotropin receptor-blocking monoclonal antibody. Novel treatment strategies have also become available in GO. Mycophenolate significantly increased the overall response rate combined with standard glucocorticoid (GC) treatment compared to GC monotherapy. Tocilizumab, an anti-interleukin 6 receptor monoclonal antibody, displayed strong anti-inflammatory action in GC-resistant cases. Teprotumumab, an anti-insulin-like growth factor 1 receptor monoclonal antibody, resulted in remarkable improvement in terms of disease activity, proptosis, and diplopia. Further, rituximab appears to be useful in active disease of recent onset without impending dysthyroid optic neuropathy. Key Messages: Therapeutic advances will continue to optimize our management of GH and associated orbitopathy in an effective and safe manner.<\/jats:p>","DOI":"10.1159\/000508789","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T17:00:39Z","timestamp":1597078839000},"page":"17-30","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":30,"title":["Novel Approaches for Immunosuppression in Graves\u2019 Hyperthyroidism and Associated Orbitopathy"],"prefix":"10.1530","volume":"9","author":[{"given":"Alan\u00a0Chun\u00a0Hong","family":"Lee","sequence":"first","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George\u00a0J.","family":"Kahaly","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"issue":"4","key":"2026070713094693300_ref1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur Thyroid J","ISSN":"https:\/\/id.crossref.org\/issn\/2235-0640","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J","ISSN":"https:\/\/id.crossref.org\/issn\/2235-0640","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-16-0576","article-title":"Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study","volume":"176","author":"Dekkers","year":"2017","journal-title":"Eur J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"key":"2026070713094693300_ref4","doi-asserted-by":"publisher","first-page":"thy.2019.0543","DOI":"10.1089\/thy.2019.0543","article-title":"Incidence and mortality of myocardial infarction and stroke in patients with hyperthyroidism: A nationwide cohort study in Korea","author":"Kim","year":"2020","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"key":"2026070713094693300_ref5","doi-asserted-by":"crossref","unstructured":"Ponto\n              KA\n            , HommelG, PitzS, ElfleinH, PfeifferN, KahalyGJ: Quality of life in a german graves orbitopathy population. Am J Ophthalmol 2011;152:483-490 e481. 10.1016\/j.ajo.2011.02.018","DOI":"10.1016\/j.ajo.2011.02.018"},{"issue":"7","key":"2026070713094693300_ref6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.autrev.2017.12.012","article-title":"Quality of life and neuropsychiatric disorders in patients with Graves\u2019 Orbitopathy: current concepts","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun Rev","ISSN":"https:\/\/id.crossref.org\/issn\/1568-9972","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","article-title":"Public health relevance of Graves\u2019 orbitopathy","volume":"98","author":"Ponto","year":"2013","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/thy.2019.0132","article-title":"Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves\u2019 Disease: A Nationwide Population-Based Study","volume":"30","author":"Brito","year":"2020","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S2213-8587(20)30025-5","article-title":"Methimazole and risk of acute pancreatitis","volume":"8","author":"Brix","year":"2020","journal-title":"Lancet Diabetes Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/2213-8587","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000339444","article-title":"2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism","volume":"1","author":"Wiersinga","year":"2012","journal-title":"Eur Thyroid J","ISSN":"https:\/\/id.crossref.org\/issn\/2235-0640","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4158\/EP-2019-0363","article-title":"Tsh Receptor Antibodies: Relevance & Utility","volume":"26","author":"Kahaly","year":"2020","journal-title":"Endocr Pract","ISSN":"https:\/\/id.crossref.org\/issn\/1530-891X","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41433-018-0285-y","article-title":"B cells in Graves\u2019 Orbitopathy: more than just a source of antibodies?","volume":"33","author":"Salvi","year":"2019","journal-title":"Eye (Lond)","ISSN":"https:\/\/id.crossref.org\/issn\/0950-222X","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref14","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clim.2008.09.007","article-title":"Treatment of Graves\u2019 disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies","volume":"130","author":"El Fassi","year":"2009","journal-title":"Clin Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/1521-6616","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1530\/EJE-08-0084","article-title":"Rituximab in relapsing Graves\u2019 disease, a phase II study","volume":"159","author":"Heemstra","year":"2008","journal-title":"Eur J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"issue":"7","key":"2026070713094693300_ref17","first-page":"e163","article-title":"Systemic adverse events following rituximab therapy in patients with Graves\u2019 disease","volume":"34","author":"El Fassi","year":"2011","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/1720-8386","issn-type":"print"},{"issue":"S2","key":"2026070713094693300_ref18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13223-018-0282-5","article-title":"Allergen-specific immunotherapy","volume":"14","author":"Moote","year":"2018","journal-title":"Allergy Asthma Clin Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/1710-1484","issn-type":"print"},{"issue":"402","key":"2026070713094693300_ref19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1126\/scitranslmed.aaf7779","article-title":"Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes","volume":"9","author":"Alhadj Ali","year":"2017","journal-title":"Sci Transl Med","ISSN":"https:\/\/id.crossref.org\/issn\/1946-6234","issn-type":"print"},{"issue":"11","key":"2026070713094693300_ref20","doi-asserted-by":"publisher","first-page":"e955","DOI":"10.1212\/WNL.0000000000005118","article-title":"Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis","volume":"90","author":"Chataway","year":"2018","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"issue":"9","key":"2026070713094693300_ref21","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/en.2018-00306","article-title":"Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice","volume":"159","author":"Jansson","year":"2018","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"issue":"7","key":"2026070713094693300_ref22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves\u2019 Hyperthyroidism: A Phase I Study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"10","key":"2026070713094693300_ref23","first-page":"764","article-title":"[Costimulatory molecule CD40 expression in thyroid tissue of Graves\u2019 disease patients and its immune pathogenetic significance]","volume":"93","author":"Wang","year":"2013","journal-title":"Zhonghua Yi Xue Za Zhi","ISSN":"https:\/\/id.crossref.org\/issn\/0376-2491","issn-type":"print"},{"issue":"12","key":"2026070713094693300_ref24","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1111\/ajt.14872","article-title":"Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody","volume":"18","author":"Ristov","year":"2018","journal-title":"Am J Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/1600-6135","issn-type":"print"},{"key":"2026070713094693300_ref25","doi-asserted-by":"publisher","first-page":"102364","DOI":"10.1016\/j.jaut.2019.102364","article-title":"Sj\u00f6gren\u2019s syndrome: old and new therapeutic targets","volume":"110","author":"Mavragani","year":"2020","journal-title":"J Autoimmun","ISSN":"https:\/\/id.crossref.org\/issn\/0896-8411","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/clinem\/dgz013","article-title":"A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref27","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves\u2019 Hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"12","key":"2026070713094693300_ref28","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1210\/en.2008-0836","article-title":"A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism","volume":"149","author":"Neumann","year":"2008","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"issue":"7","key":"2026070713094693300_ref29","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1210\/en.2010-0199","article-title":"A small molecule inverse agonist for the human thyroid-stimulating hormone receptor","volume":"151","author":"Neumann","year":"2010","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1210\/jc.2010-1935","article-title":"A new small-molecule antagonist inhibits Graves\u2019 disease antibody activation of the TSH receptor","volume":"96","author":"Neumann","year":"2011","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"7","key":"2026070713094693300_ref31","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1111\/j.1476-5381.2011.01709.x","article-title":"Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor","volume":"165","author":"van Koppen","year":"2012","journal-title":"Br J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1188","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1210\/en.2013-1835","article-title":"A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice","volume":"155","author":"Neumann","year":"2014","journal-title":"Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7227","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves\u2019 Orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref34","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1365-2265.2010.03831.x","article-title":"Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample","volume":"73","author":"Evans","year":"2010","journal-title":"Clin Endocrinol (Oxf)","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13317-011-0025-9","article-title":"In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)","volume":"3","author":"Furmaniak","year":"2011","journal-title":"Auto Immun Highlights","ISSN":"https:\/\/id.crossref.org\/issn\/2038-0305","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40618-019-01116-4","article-title":"Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy","volume":"43","author":"Hai","year":"2020","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"7","key":"2026070713094693300_ref38","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00204-014-1247-1","article-title":"Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update","volume":"88","author":"Staatz","year":"2014","journal-title":"Arch Toxicol","ISSN":"https:\/\/id.crossref.org\/issn\/0340-5761","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1046\/j.1523-1755.2000.00140.x","article-title":"Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney","volume":"58","author":"Badid","year":"2000","journal-title":"Kidney Int","ISSN":"https:\/\/id.crossref.org\/issn\/0085-2538","issn-type":"print"},{"issue":"11","key":"2026070713094693300_ref40","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1136\/bjo.87.11.1397","article-title":"Mycophenolate mofetil inhibits human Tenon fibroblast proliferation by guanosine depletion","volume":"87","author":"Heinz","year":"2003","journal-title":"Br J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1161","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/01.TP.0000101822.50960.AB","article-title":"Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation","volume":"77","author":"Azzola","year":"2004","journal-title":"Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0041-1337","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/FTD.0b013e3181e44260","article-title":"Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function","volume":"32","author":"Petrova","year":"2010","journal-title":"Ther Drug Monit","ISSN":"https:\/\/id.crossref.org\/issn\/0163-4356","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1124\/jpet.106.117051","article-title":"In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil","volume":"321","author":"Roos","year":"2007","journal-title":"J Pharmacol Exp Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3565","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1006\/cyto.2002.0885","article-title":"Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms","volume":"19","author":"Miljkovic","year":"2002","journal-title":"Cytokine","ISSN":"https:\/\/id.crossref.org\/issn\/1043-4666","issn-type":"print"},{"issue":"7","key":"2026070713094693300_ref45","doi-asserted-by":"publisher","first-page":"E1183","DOI":"10.1210\/jc.2013-4182","article-title":"Possible targets for nonimmunosuppressive therapy of Graves\u2019 orbitopathy","volume":"99","author":"Zhang","year":"2014","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"2026070713094693300_ref46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbi.2018.09.020","article-title":"Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1\u03b2 mediated PI3K\/AKT\/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy","volume":"75","author":"Mazumder","year":"2019","journal-title":"Brain Behav Immun","ISSN":"https:\/\/id.crossref.org\/issn\/0889-1591","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref47","first-page":"125","article-title":"[Immunosuppressive therapies in patients with Graves\u2019 ophthalmopathy]","volume":"43","author":"Wang","year":"2004","journal-title":"Zhonghua Nei Ke Za Zhi","ISSN":"https:\/\/id.crossref.org\/issn\/0578-1426","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u2019 orbitopathy","volume":"86","author":"Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/2213-8587","issn-type":"print"},{"issue":"6","key":"2026070713094693300_ref50","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40618-019-01161-z","article-title":"Systemic safety analysis of mycophenolate in Graves\u2019 orbitopathy","volume":"43","author":"Lee","year":"2020","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-2249.2000.01335.x","article-title":"Both Th1- and Th2-derived cytokines in serum are elevated in Graves\u2019 ophthalmopathy","volume":"121","author":"Wakelkamp","year":"2000","journal-title":"Clin Exp Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref52","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1038\/s41598-018-29113-2","article-title":"Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy","volume":"8","author":"Kishazi","year":"2018","journal-title":"Sci Rep","ISSN":"https:\/\/id.crossref.org\/issn\/2045-2322","issn-type":"print"},{"key":"2026070713094693300_ref53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2017.01.014","article-title":"Orbital fibroblasts of Graves\u2019 orbitopathy stimulated with proinflammatory cytokines promote B cell survival by secreting BAFF","volume":"446","author":"Tang","year":"2017","journal-title":"Mol Cell Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0303-7207","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1530\/eje.1.02242","article-title":"The effects of tumour necrosis factor-alpha and interleukin1 on an in vitro model of thyroid-associated ophthalmopathy; contrasting effects on adipogenesis","volume":"155","author":"Cawood","year":"2006","journal-title":"Eur J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref55","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/bjo.2010.192302","article-title":"Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves\u2019 ophthalmopathy","volume":"95","author":"van Steensel","year":"2011","journal-title":"Br J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1161","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/01676830590912562","article-title":"Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy","volume":"24","author":"Durrani","year":"2005","journal-title":"Orbit","ISSN":"https:\/\/id.crossref.org\/issn\/0167-6830","issn-type":"print"},{"issue":"10-12","key":"2026070713094693300_ref57","first-page":"457","article-title":"Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy","volume":"109","author":"Komorowski","year":"2007","journal-title":"Klin Oczna","ISSN":"https:\/\/id.crossref.org\/issn\/0023-2157","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5114\/ceji.2019.92803","article-title":"Etanercept in the treatment of Graves\u2019 ophthalmopathy with primary hypothyroidism and rheumatoid arthritis","volume":"44","author":"Boskovic","year":"2019","journal-title":"Cent Eur J Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/1426-3912","issn-type":"print"},{"issue":"12","key":"2026070713094693300_ref59","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye (Lond)","ISSN":"https:\/\/id.crossref.org\/issn\/0950-222X","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref60","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","article-title":"Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease","volume":"30","author":"Ayabe","year":"2014","journal-title":"Ophthal Plast Reconstr Surg","ISSN":"https:\/\/id.crossref.org\/issn\/0740-9303","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref61","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref62","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"6","key":"2026070713094693300_ref63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40618-019-01161-z","article-title":"Systemic safety analysis of mycophenolate in Graves\u2019 orbitopathy","volume":"43","author":"Lee","year":"2020","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"key":"2026070713094693300_ref64","doi-asserted-by":"publisher","first-page":"1120672119845224","DOI":"10.1177\/1120672119845224","article-title":"The effects of Rituximab on Graves\u2019orbitopathy: A retrospective study of 14 patients","author":"Eid","year":"2019","journal-title":"Eur J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/1120-6721","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref65","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.4049\/jimmunol.175.2.1310","article-title":"IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy","volume":"175","author":"Chen","year":"2005","journal-title":"J Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref66","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1167\/iovs.08-2328","article-title":"Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1","volume":"50","author":"Hwang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0146-0404","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref67","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/thy.2009.0278","article-title":"A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves\u2019 orbital preadipocyte fibroblasts","volume":"20","author":"Kumar","year":"2010","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref68","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1161","issn-type":"print"},{"issue":"10","key":"2026070713094693300_ref69","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1089\/105072501753210984","article-title":"Interleukin-6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves\u2019 ophthalmopathy","volume":"11","author":"Jyonouchi","year":"2001","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"11","key":"2026070713094693300_ref70","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1210\/jc.2017-01349","article-title":"Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy","volume":"102","author":"Fang","year":"2017","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref71","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1210\/jc.2018-01626","article-title":"Insights Into Local Orbital Immunity: Evidence for the Involvement of the Th17 Cell Pathway in Thyroid-Associated Ophthalmopathy","volume":"104","author":"Fang","year":"2019","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"2026070713094693300_ref72","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","article-title":"IL-6: a cytokine at the crossroads of autoimmunity","volume":"55","author":"Jones","year":"2018","journal-title":"Curr Opin Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0952-7915","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/08916939708996275","article-title":"High circulating IL-6 level in Graves\u2019 ophthalmopathy","volume":"25","author":"Moln\u00e1r","year":"1997","journal-title":"Autoimmunity","ISSN":"https:\/\/id.crossref.org\/issn\/0891-6934","issn-type":"print"},{"key":"2026070713094693300_ref74","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01174-8","article-title":"Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids","author":"Xu","year":"2020","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref75","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthal Plast Reconstr Surg","ISSN":"https:\/\/id.crossref.org\/issn\/0740-9303","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref76","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1097\/IOP.0000000000000730","article-title":"Clinical Response to Tocilizumab in Severe Thyroid Eye Disease","volume":"33","author":"Sy","year":"2017","journal-title":"Ophthal Plast Reconstr Surg","ISSN":"https:\/\/id.crossref.org\/issn\/0740-9303","issn-type":"print"},{"key":"2026070713094693300_ref77","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ajoc.2017.07.001","article-title":"Tocilizumab as a steroid sparing agent for the treatment of Graves\u2019 orbitopathy","volume":"7","author":"Russell","year":"2017","journal-title":"Am J Ophthalmol Case Rep","ISSN":"https:\/\/id.crossref.org\/issn\/2451-9936","issn-type":"print"},{"issue":"6","key":"2026070713094693300_ref78","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2174\/1871530318666180702150243","article-title":"Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab","volume":"18","author":"Canas","year":"2018","journal-title":"Endocr Metab Immune Disord Drug Targets","ISSN":"https:\/\/id.crossref.org\/issn\/1871-5303","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref79","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/09273948.2018.1545914","article-title":"Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves\u2019 Ophthalmopathy, a Report of Three Cases","volume":"28","author":"Maldiney","year":"2020","journal-title":"Ocul Immunol Inflamm","ISSN":"https:\/\/id.crossref.org\/issn\/0927-3948","issn-type":"print"},{"key":"2026070713094693300_ref80","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9394","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref81","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40618-017-0608-z","article-title":"Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves\u2019 orbitopathy?","volume":"40","author":"Bartalena","year":"2017","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref82","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity","ISSN":"https:\/\/id.crossref.org\/issn\/0891-6934","issn-type":"print"},{"issue":"12","key":"2026070713094693300_ref83","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"6","key":"2026070713094693300_ref84","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref85","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","article-title":"Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis","volume":"178","author":"Douglas","year":"2007","journal-title":"J Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"8","key":"2026070713094693300_ref86","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref87","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev","ISSN":"https:\/\/id.crossref.org\/issn\/0163-769X","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref88","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1210\/jc.2012-1771","article-title":"Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy","volume":"98","author":"Minich","year":"2013","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref89","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40618-018-0943-8","article-title":"Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy","volume":"42","author":"Marin\u00f2","year":"2019","journal-title":"J Endocrinol Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0391-4097","issn-type":"print"},{"issue":"6","key":"2026070713094693300_ref90","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 Receptor Cross Talk in Graves\u2019 Ophthalmopathy Pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref91","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1089\/thy.2018.0089","article-title":"Evidence That Graves\u2019 Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors","volume":"28","author":"Marcus-Samuels","year":"2018","journal-title":"Thyroid","ISSN":"https:\/\/id.crossref.org\/issn\/1050-7256","issn-type":"print"},{"issue":"9","key":"2026070713094693300_ref92","doi-asserted-by":"publisher","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"issue":"6","key":"2026070713094693300_ref93","doi-asserted-by":"publisher","first-page":"e0130322","DOI":"10.1371\/journal.pone.0130322","article-title":"TSH-Mediated TNF\u03b1 Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"issue":"18","key":"2026070713094693300_ref94","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for Thyroid-Associated Ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref95","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"2","key":"2026070713094693300_ref96","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41433-018-0321-y","article-title":"Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis","volume":"33","author":"Douglas","year":"2019","journal-title":"Eye (Lond)","ISSN":"https:\/\/id.crossref.org\/issn\/0950-222X","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref97","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1055\/s-0037-1598192","article-title":"Orbital Decompression for Thyroid Eye Disease","volume":"31","author":"Braun","year":"2017","journal-title":"Semin Plast Surg","ISSN":"https:\/\/id.crossref.org\/issn\/1535-2188","issn-type":"print"},{"issue":"5","key":"2026070713094693300_ref98","doi-asserted-by":"publisher","first-page":"D27","DOI":"10.1530\/EJE-19-0389","article-title":"Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?","volume":"181","author":"Smith","year":"2019","journal-title":"Eur J Endocrinol","ISSN":"https:\/\/id.crossref.org\/issn\/0804-4643","issn-type":"print"},{"issue":"6","key":"2026070713094693300_ref99","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/cen.13834","article-title":"Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach","volume":"89","author":"Sipkova","year":"2018","journal-title":"Clin Endocrinol (Oxf)","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"issue":"1","key":"2026070713094693300_ref100","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol (Oxf)","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0664","issn-type":"print"},{"issue":"3","key":"2026070713094693300_ref101","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/IOP.0b013e3180500d57","article-title":"Rapamycin for treatment of refractory dysthyroid compressive optic neuropathy","volume":"23","author":"Chang","year":"2007","journal-title":"Ophthal Plast Reconstr Surg","ISSN":"https:\/\/id.crossref.org\/issn\/0740-9303","issn-type":"print"},{"issue":"4","key":"2026070713094693300_ref102","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41433-019-0340-3","article-title":"Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves\u2019 orbitopathy","volume":"33","author":"Roos","year":"2019","journal-title":"Eye (Lond)","ISSN":"https:\/\/id.crossref.org\/issn\/0950-222X","issn-type":"print"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/508789","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/9\/1_Suppl\/17\/36296\/etj508789.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/9\/1_Suppl\/17\/36296\/etj508789.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:49:29Z","timestamp":1783446569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/9\/1_Suppl\/17\/4927\/Novel-Approaches-for-Immunosuppression-in-Graves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":102,"journal-issue":{"issue":"1_Suppl","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000508789","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}